Orion

January 31, 2019

Titan could give Erleada a fighting chance

But Erleada, Johnson & Johnson’s next-gen prostate cancer therapy, still needs to outperform the incumbent, Zytiga.

August 24, 2018

Upcoming events – Pivotal data readouts for Galapagos and Bayer

Galapagos and Bayer/Orion will both report phase III data this quarter – the former with filgotinib in arthritis and the latter with darolutamide in prostate cancer.

November 22, 2017

Therapy focus – Cytokinetics crash puts spotlight on new ALS approaches

November 13, 2017

Alnylam: The $12bn company with the $2bn war chest

August 29, 2017

ESC 2017 – Medicines Company forges on alone

August 23, 2017

ESC 2017 preview – What outcomes might mean for incomes

March 18, 2017

ACC – As Amgen goes, so goes Medicines Company

March 18, 2017

ACC – As Amgen goes, so goes Medicines Company

March 06, 2017

ACC – Repatha’s next challenge is expectations